NCT07680205RecruitingPhase 2
An Experimental Study of Belzutifan Impact on Catecholamine Metabolism
An Experimental Pilot Study to Investigate Changes in Catecholamine Synthesis and Metabolism in Patients With Molecularly Profiled Phaeochromocytoma and Paraganglioma Taking Belzutifan
Source: ClinicalTrials.gov · Last updated 2 Jul 2026
Brief summary (registry, in English)
To investigate the impact of a medication called Belzutifan on the production and subsequent metabolism of adrenaline and noradrenaline collectively termed 'catecholamines'. The study aims to identify changes in the production and metabolism of catecholamines by measuring the substance which starts the chain of catecholamine metabolism called tyrosine in patients before, during and after 5 days of taking Belzutifan 120mg daily.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 23 Jun 2026
- Start date
- 27 Apr 2026
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Diseases
- Childhood cancers
- NCT number
- NCT07680205
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 12
- From 27 Apr 2026 to the primary completion date, 30 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Is on medications which may interfere with belzutifan pharmacokinetics and that cannot be stopped for the duration of the study and for 7 days after the study period (everolimus, omeprazole, esomeprazole, Fluconazole, fluoxetine, Voriconazole, Sirolimus)
Other illness
- Has clinically significant cardiac disease, including unstable angina, acute myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass graft surgery (CABG) ≤6 months from Day 1 of study drug administration, or New York Heart Association Class III or IV congestive heart failure. Medically controlled arrhythmia stable on medication is permitted.
- Has a co-existing malignancy (in addition to PPGL)
- Has a known diagnosis of HIV, hepatitis B or hepatitis C
Other
- Has hypoxia, or requires intermittent supplemental oxygen, or requires chronic supplemental oxygen.
- Has a Hb \< 100g/dL
Who the study is looking for
- Adult patients \> 18 years
- Patients must have a biochemically confirmed diagnosis of a phaeochromocytoma or paraganglioma using plasma metanephrines or 24- hour urinary metanephrines and plasma or urinary metanephrines should be at least 1.5 times the upper limit of the normal reference range.
- Female patients of child-bearing potential must have a negative serum pregnancy test result within 3 days before first administration of study drug
- Able to provide informed consent
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cambridge University Hospitals NHS Foundation Trust Coordinator of this site? Confirm its status | Cambridge | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.